Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.
30 Oct: open ₹5.62, high ₹5.64, low ₹5.53
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,267
Vivimed Labs share news and announcements
642 announcements, routine notices left out, newest first. Page 8 of 13.
Apr 2017
20 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned "Vivimed Labs Mulls Selling stake in Chennai Formulation plant". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.17 Apr · Disclosure
17 Apr · Legal
The exchange asked on 13 Apr 2017
Mar 2017
Feb 2017
15 Feb · Board meeting
14 Feb · Results
7 Feb · Meeting
Jan 2017
12 Jan · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to announcement dated 12-Jan-2017, regarding Outcome of Board Meeting held on January 12, 2017.On basis of above the Company is required to clarify following:1. Reasons for termination.2. Names of the investors;The response of the Company is awaited.12 Jan · Board meeting
Dec 2016
12 Dec · Limited Review Report
Nov 2016
29 Nov · Business
21 Nov · Analysts
12 Nov · Results
Oct 2016
1 Oct · Regulation 44(3) of SEBI (LODR), Reg., 2015
Sep 2016
22 Sep · Legal
The exchange asked on 21 Sep 2016
Aug 2016
Jul 2016
25 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to announcement dated July 22, 2016, regarding press release dated July 22, 2016 title " Klar Sehen Private Limited, a wholly owned subsidiary of Vivimed announces the sale of certain products along with associated trademarks Total consideration for the identified products and trademarks is Rs. 730 million".On basis of above the Company is required to clarify following:1. The amount and percentage of the turnover or revenue or income and net worth contributed by such products along with associated trademarks during the last financial year;2. Date on which the agreement for sale has been entered into;3. The expected date of completion of sale/disposal;4. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.5. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".The response of the Company is awaited.
May 2016
31 May · Results
Apr 2016
Mar 2016
Feb 2016
25 Feb · Regulation 44(3) of SEBI (LODR), Reg., 2015
Jan 2016
11 Jan · Board meeting
Dec 2015